Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms
AssigneeDana-Farber Cancer Institute, Inc.
InventorsAlexander Gusev, Dennis Grishin
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsAlexander Gusev, Dennis Grishin
Estimating the term…
The disclosure provides a method for determining whether a subject is at risk of developing or will develop cancer. The biomarker may be a single nucleotide polymorphism (SNP). An SNP may be referred to by an rsID number, which is a unique number used to identify a specific SNP. Information about SNPs with rsID numbers are maintained by the National Library of Medicine, which provides the SNP's position in the genome, the alleles present (the reference nucleotide in a so-called wild-type condition and the altered nucleotide), the frequency at which the altered nucleotide has previously been detected, and its type.
-40. (canceled)
A method, comprising:
A method of generating a predictive model for determining genomic regions that increase cancer risk heritability, comprising:
A system, comprising:
Dependencies are inferred from the claim text.